In Matrico®Reagents & Assays
leveraging tissue-specific extracellular matrixbiomaterials for predictive drug testing
News
Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant
A cross-disciplinary team of surgeons and bioengineers from Vanderbilt University, Columbia University, Stanford University, New York-Presbyterian Hospital, State University of New York Downstate Medical Center, and Xylyx Bio collaborated to develop a new technique called ‘xenogeneic cross-circulation’, which involves temporarily connecting a human donor lung to a live pig to support and resuscitate the human […]
Read MoreXylyx Bio collaboration reveals new insights into tumor drug resistance
Researchers at the University of Illinois applied Xylyx Bio’s IN SITE Metastasis Kit to evaluate a cancer therapeutic. Molecular Cancer Research, a journal of the American Association for Cancer Research, recently published the peer-reviewed manuscript. The results showed that dietary interventions may increase the efficacy of treatment for breast cancer metastases. Read the Publication! Watch […]
Read MoreXylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute
Xylyx Bio has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF).
Read MoreXylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery
Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research.
Read MoreResearchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant
A cross-disciplinary team of surgeons and bioengineers from Vanderbilt University, Columbia University, Stanford University, New York-Presbyterian Hospital, State University of New York Downstate Medical Center, and Xylyx Bio collaborated to develop a new technique called ‘xenogeneic cross-circulation’, which involves temporarily connecting a human donor lung to a live pig to support and resuscitate the human […]
Read MoreXylyx Bio collaboration reveals new insights into tumor drug resistance
Researchers at the University of Illinois applied Xylyx Bio’s IN SITE Metastasis Kit to evaluate a cancer therapeutic. Molecular Cancer Research, a journal of the American Association for Cancer Research, recently published the peer-reviewed manuscript. The results showed that dietary interventions may increase the efficacy of treatment for breast cancer metastases. Read the Publication! Watch […]
Read MoreXylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute
Xylyx Bio has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF).
Read MoreXylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery
Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research.
Read MoreVIVIQ™ Skin Health Launches to Bring Clinical Benefits to Prestige Skincare
Xylyx Bio launched VIVIQ Skin Health, a prestige skincare brand with the world’s first and only skincare product powered by Matrikynes® biotechnology, a clinically proven blend of extracellular matrix peptides designed to bring clinic-worthy results to consumer skincare.
Read MoreXylyx Bio and Cell&Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery
New York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology.
Read MoreXYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery
Xylyx Bio now offers specialized contract R&D services based on its highly predictive IN MATRICO™ platform. Xylyx Bio’s custom assays incorporate human disease-specific extracellular matrix (ECM) substrates combined with clinically relevant informatics to better represent human biology and reliably de-risk drug discovery through early efficacy signals that simultaneously reduce costs and development time.
Read MoreXYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery
Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH.
Read More
Previous
Next
